SynthesisJournal of clinical hypertension (Greenwich, Conn.)2022
Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global prevalence of nocturnal hypertension: systematic review and meta-analysis.BMC public health · 2026Pooled it
- Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.Nutrients · 2025Pooled it
- Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2022Pooled it
- Effects of bedtime melatonin treatment on blood pressure and arterial stiffness: a three-month, randomized, placebo-controlled crossover study in individuals with type 2 diabetes mellitus.Acta diabetologica · 2026Article
- Detecting the Non-Dipper Phenotype in Adolescents Exposed to Nighttime Screen Use-Digital Chronotoxicity as a Proposed Integrative Framework: A Narrative Review of Ambulatory Blood Pressure Monitoring, Subclinical Biomarkers, and Emerging Wearable and AI-Based Screening.Diagnostics (Basel, Switzerland) · 2026Review
- Unlocking the potential of circadian biology for cardiovascular health.Physiological reviews · 2026Review
- Exogenous Melatonin and Sleep Quality: A Scoping Review of Systematic Reviews.Journal of clinical pharmacology · 2026Review
- Melatonin for blood pressure control in adults.The Cochrane database of systematic reviews · 2025Article
- Circadian Rhythm Disruptions and Cardiovascular Disease Risk: The Special Role of Melatonin.Current issues in molecular biology · 2025Review
- Review
- Article
- New Perspectives on the Role and Therapeutic Potential of Melatonin in Cardiovascular Diseases.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- Non-Dipping Blood Pressure or Nocturnal Hypertension: Does One Matter More?Current hypertension reports · 2024Review
- The Effect of Melatonin Supplement on High Arterial Blood Pressure: An Overview from Clinicaltrials.gov.Journal of multidisciplinary healthcare · 2024Review
- Changes in Melatonin Concentration in a Clinical Observation Study under the Influence of Low-Frequency Magnetic Fields (Magnetic Stimulation in Men with Low Back Pain)-Results of Changes in an Eight-Point Circadian Profile.International journal of molecular sciences · 2023Observational
- Depression Pathophysiology: Astrocyte Mitochondrial Melatonergic Pathway as Crucial Hub.International journal of molecular sciences · 2022Review
- Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral melatonin is a potential alternative treatment for hypertension and nocturnal hypertension. However, high-quality and relevant meta-analyses are lacking. This meta-analysis aimed to investigate whether oral melatonin supplementation reduces daytime/asleep blood pressure and cardiovascular risk, improves sleep quality, and is well-tolerated compared with placebo. Relevant articles were searched in multiple databases, including MEDLINE, EMBASE, CINAHL Complete, and the Cochrane Library, from their inception to June 2021. The included studies were randomized controlled trials recruiting patients with hypertension, using oral melatonin as the sole intervention, and investigating its effect on blood pressure. The mean out-of-office (including 24-h, daytime, and asleep) systolic and diastolic blood pressures, sleep quality, and side effects were compared between the melatonin and placebo arms using pairwise random-effect meta-analyses. A risk of bias assessment was performed using the Cochrane risk-of-bias tool. Four studies were included in the analysis and only one study was considered to have a low risk of bias. No study reported on cardiovascular risk or outcomes. Only controlled-release melatonin (not an immediate-release preparation) reduced asleep systolic blood pressure by 3.57 mm Hg (95% confidence interval: -7.88 to .73; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.